Promising cancer drug trial halted early despite genetic target
NCT ID NCT05023655
First seen Mar 30, 2026 · Last updated May 11, 2026 · Updated 4 times
Summary
This study tested a drug called tazemetostat in people with advanced solid tumors that have a specific genetic change (ARID1A mutation). The drug works by blocking a protein (EZH2) that helps these tumors grow. The trial aimed to see if the drug could shrink tumors or stop them from growing, but it was stopped early. About 20 participants were planned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States
Conditions
Explore the condition pages connected to this study.